Literature DB >> 11056157

ATP-stimulated release of interleukin (IL)-1beta and IL-18 requires priming by lipopolysaccharide and is independent of caspase-1 cleavage.

V B Mehta1, J Hart, M D Wewers.   

Abstract

Interleukin (IL)-1beta and IL-18 are structurally similar proteins that require caspase-1 processing for activation. Both proteins are released from the cytosol by unknown pathway(s). To better characterize the release pathway(s) for IL-1beta and IL-18 we evaluated the role of lipopolysaccharide priming, of interleukin-1beta-converting enzyme (ICE) inhibition, of human purinergic receptor (P2X(7)) function, and of signaling pathways in human monocytes induced by ATP. Monocytes rapidly processed and released both IL-1beta and IL-18 after exogenous ATP. Despite its constitutive cytosolic presence, IL-18 required lipopolysaccharide priming for the ATP-induced release. Neither IL-1beta nor IL-18 release was prevented by ICE inhibition, and IL-18 release was not induced by ICE activation itself. Release of both cytokines was blocked completely by a P2X7 receptor antagonist, oxidized ATP, and partially by an antibody to P2X(7) receptor. In evaluating the signaling components involved in the ATP effect, we identified that the protein-tyrosine kinase inhibitor, AG126, produced a profound inhibition of both ICE activation as well as release of IL-1beta/IL-18. Taken together, these results suggest that, although synthesis of IL-1beta and IL-18 differ, ATP-mediated release of both cytokines requires a priming step but not proteolytically functional caspase-1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11056157     DOI: 10.1074/jbc.M006814200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  106 in total

Review 1.  A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases.

Authors:  Nishkantha Arulkumaran; Robert J Unwin; Frederick Wk Tam
Journal:  Expert Opin Investig Drugs       Date:  2011-04-21       Impact factor: 6.206

2.  Synergic effects of mycoplasmal lipopeptides and extracellular ATP on activation of macrophages.

Authors:  Takeshi Into; Mari Fujita; Tsugumi Okusawa; Akira Hasebe; Manabu Morita; Ken-Ichiro Shibata
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

3.  Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes.

Authors:  Cristina Andrei; Paola Margiocco; Alessandro Poggi; Lavinia V Lotti; M R Torrisi; Anna Rubartelli
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-10       Impact factor: 11.205

Review 4.  Interleukin-18 as a potential target in inflammatory arthritis.

Authors:  J A Gracie
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

Review 5.  IL-1beta: an endosomal exit.

Authors:  Mark D Wewers
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-06       Impact factor: 11.205

6.  Functional activity of human monocytes exposed to lipopolysaccharides of different structure.

Authors:  M G Vinokurov; M M Yurinskaya; I R Prokhorenko; S V Prokhorenko; S V Grachev
Journal:  Dokl Biol Sci       Date:  2004 Mar-Apr

Review 7.  P2X ion channel receptors and inflammation.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2016-01-06       Impact factor: 3.765

Review 8.  Pharmacology of P2X channels.

Authors:  Joel R Gever; Debra A Cockayne; Michael P Dillon; Geoffrey Burnstock; Anthony P D W Ford
Journal:  Pflugers Arch       Date:  2006-04-29       Impact factor: 3.657

9.  Extracellular nucleotides mediate LPS-induced neutrophil migration in vitro and in vivo.

Authors:  Filip Kukulski; Fethia Ben Yebdri; Julie Lefebvre; Michel Warny; Philippe A Tessier; Jean Sévigny
Journal:  J Leukoc Biol       Date:  2007-02-22       Impact factor: 4.962

10.  Tyrosine phosphatase inhibition induces an ASC-dependent pyroptosis.

Authors:  Mohammed G Ghonime; Obada R Shamaa; Ramadan A Eldomany; Mikhail A Gavrilin; Mark D Wewers
Journal:  Biochem Biophys Res Commun       Date:  2012-07-27       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.